Investment Stage – Series A & B
Definigen produces hIPSC derived hepatocytes, pancreatic beta cells and lung endothelial cells for use in drug discovery and toxicology testing for the biotech and pharma industry.
Spex Capital Ltd. (SPEX), registered in England and Wales, is authorised and regulated by the Financial Conduct Authority having Firm Reference Number 963796.
©2023 · Spex Capital
©2022 · Spex Capital